Quercetin: Difference between revisions
→Formulation of Enhanced Bioavailability
| Line 168: | Line 168: | ||
===Formulation of Enhanced Bioavailability=== | ===Formulation of Enhanced Bioavailability=== | ||
The low bioavailability of quercetin raises questions about the clinical relevance of its potential health benefits observed in vitro and in animal studies. Therefore, several strategies have been explored to enhance the absorption and stability of quercetin. | The low bioavailability of quercetin raises questions about the clinical relevance of its potential health benefits observed in vitro and in animal studies. Therefore, several strategies have been explored to enhance the absorption and stability of quercetin. The following formulations are found on the market: | ||
{| class="wikitable" style="width:100%; text-align:center;" | {| class="wikitable" style="width:100%; text-align:center;" | ||
| Line 183: | Line 183: | ||
| Quercetin Phytosomes | | Quercetin Phytosomes | ||
|Quercetin-Phospholipid | |Quercetin-Phospholipid | ||
| | | 10-20 || Improved || Significantly increases oral bioavailability compared to standard quercetin. | ||
|- | |- | ||
| Nanoparticle Formulations | | Nanoparticle Formulations | ||
| Line 189: | Line 189: | ||
| Several-fold increase || Variable, generally improved || Includes liposomal encapsulations; increased solubility and cellular uptake. | | Several-fold increase || Variable, generally improved || Includes liposomal encapsulations; increased solubility and cellular uptake. | ||
|- | |- | ||
| | | Quercetin LipoMicel | ||
| | | | ||
| | | 8-9 || || Encapsulating quercetin within a liquid micelle matrix | ||
|- | |- | ||
| Co-administration with Piperine | | Co-administration with Piperine | ||
| Line 197: | Line 197: | ||
| Approximately 20% | | Approximately 20% | ||
| Low || Inhibits metabolism of quercetin, improving its bioavailability. | | Low || Inhibits metabolism of quercetin, improving its bioavailability. | ||
|} | |} | ||